<p>Nanovery 的首席执行官 Jurek Kozyra 加入主持人 Karla Jo Helms，在《Disruption Interruption》播客中讨论分子医学的革命。Kozyra 揭示了 DNA 纳米机器人和人工智能如何将诊断等待时间从几天缩短到几小时，并加速药物开发，可能缩短十年才能上市的救命治疗的过程。</p>
<p>, /PRNewswire/ -- 将新药从发现到上市的过程是一场艰苦的马拉松，通常需要 10 到 15 年的研究、测试和监管批准。根据最近的数据，创新药物的临床开发时间在过去十年中保持停滞，平均持续时间约为 8 年。Nanovery 的创始人兼首席执行官 Jurek Kozyra 在最新一期的《Disruption Interruption podcast》中与主持人 Karla Jo Helms 坐下来，解释他是如何拆除这些障碍的。Kozyra 讨论了 DNA 纳米技术与人工智能的融合如何创造出一种新的 “寡核苷酸治疗” 时代，能够针对疾病的根本机制。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>DI: 第 212 集</p>
<p>&#34;如果你能非常具体地靶向 mRNA，那么理论上你可以治愈所有疾病，&#34; Kozyra 说。&#34;这就是为什么这个领域现在如此令人兴奋。&#34;</p>
<p><strong>传统医学的停滞</strong></p>
<p>几个世纪以来，医学一直采用 “锁和钥匙” 模型，寻找能够修复缺陷蛋白质的分子。然而，这种方法使许多疾病无法治疗，因为科学家无法找到合适的分子来匹配目标。此外，诊断过程仍然危险地缓慢；传统实验室测试的结果可能需要长达两天才能返回——在药物过量等紧急情况下，这种延迟可能是致命的。</p>
<p>制药公司也在与时间赛跑。&#34;制药公司在与 20 年的专利赛跑，而药物开发通常需要超过 10 年，&#34; Kozyra 解释道。&#34;许多疾病无法治愈，因为我们无法找到能够修复蛋白质的合适分子。但这里的希望在于，你实际上可以治愈所有疾病，因为所有蛋白质都来自 mRNA。&#34;</p>
<p>这种低效导致数十亿美元的成本和新药 90% 的失败率，限制了患者获得救命创新的机会。</p>
<p><strong>纳米机器人：快速检测的未来</strong></p>
<p>Kozyra 的解决方案在于 DNA 纳米机器人——自组装的机器，能够在 2-4 小时内检测血液样本中的疾病，这比传统方法所需的时间少得多。与科幻小说中的金属机器人不同，这些生物机器被设计为在遇到特定的 DNA 或 RNA 分子时产生荧光信号，从而实现快速、准确的现场诊断。</p>
<p>&#34;我们正在创造自组装成结构或动态设备的纳米机器人，&#34; Kozyra 表示。&#34;你只需将它们添加到样本中，让它们找到合适的标记，然后它们开始产生信号。如果你能检测到它，你就知道你的样本中到底有什么。&#34;</p>
<p>该技术在一项涉及 170 个患者样本的医院研究中已经证明了其价值。&#34;在临床环境中，我们的技术在仅仅两小时内提供了与传统测试相同或更好的结果，而不是两天，&#34; Kozyra 指出。&#34;这对紧急情况下需要立即答案的情况来说是一个游戏规则的改变。&#34;</p>
<p><strong>链接</strong> 颠覆生物技术：DNA 纳米机器人如何重写药物发现的规则，Jurek Kozyra 主讲</p>
<p>https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra</p>
<p><strong>LinkedIn:</strong> https://www.linkedin.com/in/j3ny/</p>
<p><strong>公司网站：</strong> https://nanovery.co.uk</p>
<p>《Disruption Interruption》是一个播客，你将听到当今最大行业颠覆者的声音。了解是什么激励他们带来创新，以及他们是如何克服反对意见以实现采纳的。</p>
<p>《Disruption Interruption》可以在苹果应用商店和 Spotify 上收听。</p>
<p><strong>关于 Disruption Interruption™</strong></p>
<p>颠覆正在以前所未有的规模发生，影响着各个行业——医疗科技、金融、IT、电子商务、运输、物流等——而 COVID 使他们的时间表提前了整整十年或更长时间。但这些颠覆者是谁，他们何时说过：“够了！我受够了！”？是时候与主持人 Karla Jo &#34;KJ&#34; Helms 一起颠覆和打断了，KJ 是一位资深的传播颠覆者。KJ 采访那些正在颠覆其行业并改变已经过时的经济网络的强者，揭示行业叛逆者和安静革命者的秘密，这些人揭示了改变我们经济市场和生活的共同特征——以及不那么常见的特征。访问世界上那些尽管背后有箭仍然坚持成功的关键先驱者，网址是 www.disruption-interruption.com。</p>
<p><strong>关于 Jurek Kozyra</strong></p>
<p>Jurek Kozyra 是一位开创性的深科技企业家和研究人员，在 DNA 纳米技术、人工智能和分子纳米机器的交叉领域拥有超过十年的经验。作为 Nanovery 的创始人兼首席执行官，Jurek 正在引领分子医学的变革，开发加速下一代 RNA 治疗药物发现和特征化的生物分析平台。Nanovery 已筹集超过 700 万美元，并与全球制药公司建立了合作关系，正朝着颠覆疾病诊断和治疗的方向迈进。</p>
<p>在创办 Nanovery 之前，Jurek 在学术界磨练了他的专业知识，设计基于 DNA 的纳米设备，并开创了推动计算和纳米生物学边界的算法。他的多学科方法使他能够将突破性的科学转化为商业生物技术解决方案，弥合研究与现实世界应用之间的差距。</p>
<p>在 Nanovery，Jurek 的使命是推动 RNA 药物生物分析的创新，从高通量检测开发到先进的数据分析，使复杂疾病的治疗更加安全和有效。他的工作引起了领先学术界、行业合作伙伴和跨职能团队的关注，巩固了他在生物技术领域的远见卓识。</p>
<p><strong>关于 Karla Jo Helms</strong></p>
<p>Karla Jo Helms 是 JOTO PR Disruptors™的首席传播官和反公关战略家。Karla Jo 亲身体验了当数百万美元处于风险之中时，商业是多么无情——以及公众舆论的控制往往决定了一家公司是被愉快选择，还是被残酷拒绝。作为危机管理的校友，Karla Jo 与诉讼律师、私人调查员和媒体合作，帮助恢复企业的良好声誉，使其重新赢得公众的信任——Karla Jo 秉持一次性做对的伦理，不依赖第二次机会，竭尽所能追求卓越。Helms 在全球范围内就公共关系发表演讲，探讨公关行业如何迷失方向，以及在正确的手中，企业如何利用反公关的力量来推动市场并影响市场认知。</p>
<p><strong>参考文献</strong></p>
<ol>
<li>Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., &amp; Southall, N. (2023). 创新药物的临床开发时间。《自然评论：药物发现》，21(11)。doi.org/10.1038/d41573-021-00190-9</li>
</ol>
<p>媒体咨询：</p>
<p>Karla Jo Helms</p>
<p>JOTO PR™</p>
<p>727-777-4629</p>
<p>来源：Disruption Interruption</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE1Jk5ld3NJdGVtSWQ9Rkw2NDY1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTUxNjA2UFJfTkVXU19VU1BSX19fX19GTDY0NjU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE1Jk5ld3NJdGVtSWQ9Rkw2NDY1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTUxNjA2UFJfTkVXU19VU1BSX19fX19GTDY0NjU4"/></p>

医疗业 3 倍做多 - Direxion

NNOX

<p>Nanovery 的首席执行官 Jurek Kozyra 在 Disruption Interruption 播客中讨论了 DNA 纳米机器人和人工智能如何革新分子医学。这些创新旨在将药物开发时间从 10-15 年缩短到仅几个小时，可能通过靶向 mRNA 来治愈疾病。Kozyra 强调了传统医学的低效，并指出纳米机器人能够在 2-4 小时内检测血样中的疾病，显著快于传统方法。这项技术在临床环境中显示出良好的结果，标志着快速诊断和药物发现的重大进展</p>

<p><em>Jurek Kozyra, CEO of Nanovery, joins host Karla Jo Helms on the Disruption Interruption podcast to discuss revolutionizing molecular medicine. Kozyra reveals how DNA nanorobots and AI are reducing diagnostic wait times from days to hours and accelerating drug development, potentially shortening the decade-long journey to market life-saving treatments.</em></p>
<div class="lb-trans"><p>Nanovery 的首席执行官 Jurek Kozyra 加入主持人 Karla Jo Helms，在《Disruption Interruption》播客中讨论分子医学的革命。Kozyra 揭示了 DNA 纳米机器人和人工智能如何将诊断等待时间从几天缩短到几小时，并加速药物开发，可能缩短十年才能上市的救命治疗的过程。</p>
</div><p>, /PRNewswire/ -- Bringing a new drug from discovery to market is a grueling marathon that typically requires 10–15 years of research, testing, and regulatory approval. According to recent data, clinical development times for innovative drugs have remained stagnant over the last decade, with a median duration of around 8 years. Jurek Kozyra, founder and CEO of Nanovery, sits down with host Karla Jo Helms on the latest episode of the <em>Disruption Interruption podcast</em> to explain how he is dismantling these barriers. Kozyra discusses how the convergence of DNA nanotechnology and AI is creating a new era of &#34;oligo therapeutics&#34; capable of targeting the underlying mechanisms of disease.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 将新药从发现到上市的过程是一场艰苦的马拉松，通常需要 10 到 15 年的研究、测试和监管批准。根据最近的数据，创新药物的临床开发时间在过去十年中保持停滞，平均持续时间约为 8 年。Nanovery 的创始人兼首席执行官 Jurek Kozyra 在最新一期的《Disruption Interruption podcast》中与主持人 Karla Jo Helms 坐下来，解释他是如何拆除这些障碍的。Kozyra 讨论了 DNA 纳米技术与人工智能的融合如何创造出一种新的 “寡核苷酸治疗” 时代，能够针对疾病的根本机制。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>DI: Episode 212</p>
<div class="lb-trans"><p>DI: 第 212 集</p>
</div><p>&#34;If you can target mRNA very specifically, that means that in theory, you could potentially cure all diseases,&#34; says Kozyra. &#34;That's why this area is so exciting right now.&#34;</p>
<div class="lb-trans"><p>&#34;如果你能非常具体地靶向 mRNA，那么理论上你可以治愈所有疾病，&#34; Kozyra 说。&#34;这就是为什么这个领域现在如此令人兴奋。&#34;</p>
</div><p><strong>The Stagnation of Traditional Medicine</strong></p>
<div class="lb-trans"><p><strong>传统医学的停滞</strong></p>
</div><p>For centuries, medicine has operated on a &#34;lock and key&#34; model, hunting for molecules that can fix defective proteins. However, this approach leaves many diseases untreated simply because scientists cannot find the right molecule to fit the target. Furthermore, the diagnostic process remains dangerously slow; traditional lab tests can take up to two days to return results—a delay that can be fatal in emergency situations like drug overdoses.</p>
<div class="lb-trans"><p>几个世纪以来，医学一直采用 “锁和钥匙” 模型，寻找能够修复缺陷蛋白质的分子。然而，这种方法使许多疾病无法治疗，因为科学家无法找到合适的分子来匹配目标。此外，诊断过程仍然危险地缓慢；传统实验室测试的结果可能需要长达两天才能返回——在药物过量等紧急情况下，这种延迟可能是致命的。</p>
</div><p>Pharmaceutical companies are also racing against the clock. &#34;Pharma companies are racing against 20-year patents while drugs take over 10 years to develop,&#34; explains Kozyra. &#34;A lot of diseases cannot be cured because we cannot find the right molecule that will fix the protein. But the promise here is that you can actually cure potentially all diseases because all proteins come from mRNA.&#34;</p>
<div class="lb-trans"><p>制药公司也在与时间赛跑。&#34;制药公司在与 20 年的专利赛跑，而药物开发通常需要超过 10 年，&#34; Kozyra 解释道。&#34;许多疾病无法治愈，因为我们无法找到能够修复蛋白质的合适分子。但这里的希望在于，你实际上可以治愈所有疾病，因为所有蛋白质都来自 mRNA。&#34;</p>
</div><p>This inefficiency results in billions of dollars in costs and a 90% failure rate for new drugs, limiting patient access to life-saving innovations.</p>
<div class="lb-trans"><p>这种低效导致数十亿美元的成本和新药 90% 的失败率，限制了患者获得救命创新的机会。</p>
</div><p><strong>Nanorobots: The Future of Rapid Detection</strong></p>
<div class="lb-trans"><p><strong>纳米机器人：快速检测的未来</strong></p>
</div><p>Kozyra's solution lies in DNA nanorobots—self-assembling machines that can detect diseases in blood samples within 2-4 hours, a fraction of the time required by traditional methods. Unlike the metallic robots of science fiction, these biological machines are designed to produce fluorescent signals when they encounter specific DNA or RNA molecules, enabling rapid, accurate point-of-care diagnostics.</p>
<div class="lb-trans"><p>Kozyra 的解决方案在于 DNA 纳米机器人——自组装的机器，能够在 2-4 小时内检测血液样本中的疾病，这比传统方法所需的时间少得多。与科幻小说中的金属机器人不同，这些生物机器被设计为在遇到特定的 DNA 或 RNA 分子时产生荧光信号，从而实现快速、准确的现场诊断。</p>
</div><p>&#34;We are creating nanorobots that self-assemble into structures or dynamic devices,&#34; Kozyra states. &#34;You simply add them to the sample, let them find the right markers, and they start producing a signal. If you can detect it, you know exactly what is in your sample.&#34;</p>
<div class="lb-trans"><p>&#34;我们正在创造自组装成结构或动态设备的纳米机器人，&#34; Kozyra 表示。&#34;你只需将它们添加到样本中，让它们找到合适的标记，然后它们开始产生信号。如果你能检测到它，你就知道你的样本中到底有什么。&#34;</p>
</div><p>The technology has already proven its worth in a hospital study involving 170 patient samples. &#34;In a clinical setting, our technology delivered the same or better results than traditional tests in just two hours instead of two days,&#34; Kozyra notes. &#34;This is a gamechanger for emergency situations where immediate answers are critical.&#34;</p>
<div class="lb-trans"><p>该技术在一项涉及 170 个患者样本的医院研究中已经证明了其价值。&#34;在临床环境中，我们的技术在仅仅两小时内提供了与传统测试相同或更好的结果，而不是两天，&#34; Kozyra 指出。&#34;这对紧急情况下需要立即答案的情况来说是一个游戏规则的改变。&#34;</p>
</div><p><strong>Links</strong> Disrupting Biotech: How DNA Nanorobots Are Rewriting the Rules of Drug Discovery, with Jurek Kozyra</p>
<div class="lb-trans"><p><strong>链接</strong> 颠覆生物技术：DNA 纳米机器人如何重写药物发现的规则，Jurek Kozyra 主讲</p>
</div><p>https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra</p>
<div class="lb-trans"><p>https://omny.fm/shows/disruption-interruption/disrupting-biotech-how-dna-nanorobots-are-rewriting-the-rules-of-drug-discovery-with-jurek-kozyra</p>
</div><p><strong>LinkedIn:</strong> https://www.linkedin.com/in/j3ny/</p>
<div class="lb-trans"><p><strong>LinkedIn:</strong> https://www.linkedin.com/in/j3ny/</p>
</div><p><strong>Company Website:</strong> https://nanovery.co.uk</p>
<div class="lb-trans"><p><strong>公司网站：</strong> https://nanovery.co.uk</p>
</div><p>Disruption Interruption is the podcast where you will hear from today's biggest Industry Disruptors. Learn what motivated them to bring about innovation and how they overcame opposition to adoption.</p>
<div class="lb-trans"><p>《Disruption Interruption》是一个播客，你将听到当今最大行业颠覆者的声音。了解是什么激励他们带来创新，以及他们是如何克服反对意见以实现采纳的。</p>
</div><p>Disruption Interruption can be listened to in Apple's App Store and Spotify.</p>
<div class="lb-trans"><p>《Disruption Interruption》可以在苹果应用商店和 Spotify 上收听。</p>
</div><p><strong>About Disruption Interruption™</strong></p>
<div class="lb-trans"><p><strong>关于 Disruption Interruption™</strong></p>
</div><p>Disruption is happening on an unprecedented scale, impacting all manner of industries— MedTech, Finance, IT, eCommerce, shipping, logistics, and more—and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, &#34;THAT'S IT! I'VE HAD IT!&#34;? Time to Disrupt and Interrupt with host Karla Jo &#34;KJ&#34; Helms, veteran communications disruptor. KJ interviews badasses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits—and not-so-common—that are changing our economic markets… and lives. Visit the world's key pioneers that persist to success, despite arrows in their backs at www.disruption-interruption.com.</p>
<div class="lb-trans"><p>颠覆正在以前所未有的规模发生，影响着各个行业——医疗科技、金融、IT、电子商务、运输、物流等——而 COVID 使他们的时间表提前了整整十年或更长时间。但这些颠覆者是谁，他们何时说过：“够了！我受够了！”？是时候与主持人 Karla Jo &#34;KJ&#34; Helms 一起颠覆和打断了，KJ 是一位资深的传播颠覆者。KJ 采访那些正在颠覆其行业并改变已经过时的经济网络的强者，揭示行业叛逆者和安静革命者的秘密，这些人揭示了改变我们经济市场和生活的共同特征——以及不那么常见的特征。访问世界上那些尽管背后有箭仍然坚持成功的关键先驱者，网址是 www.disruption-interruption.com。</p>
</div><p><strong>About Jurek Kozyra</strong></p>
<div class="lb-trans"><p><strong>关于 Jurek Kozyra</strong></p>
</div><p>Jurek Kozyra is a pioneering deep-tech entrepreneur and researcher with over a decade of experience at the intersection of DNA nanotechnology, AI, and molecular nanomachines. As the founder and CEO of Nanovery, Jurek is leading the charge in transforming molecular medicine by developing bioanalytical platforms that accelerate the discovery and characterization of next-generation RNA therapeutics. With more than $7 million raised and partnerships with global pharmaceutical companies, Nanovery is on track to revolutionize how diseases are diagnosed and treated.</p>
<div class="lb-trans"><p>Jurek Kozyra 是一位开创性的深科技企业家和研究人员，在 DNA 纳米技术、人工智能和分子纳米机器的交叉领域拥有超过十年的经验。作为 Nanovery 的创始人兼首席执行官，Jurek 正在引领分子医学的变革，开发加速下一代 RNA 治疗药物发现和特征化的生物分析平台。Nanovery 已筹集超过 700 万美元，并与全球制药公司建立了合作关系，正朝着颠覆疾病诊断和治疗的方向迈进。</p>
</div><p>Before founding Nanovery, Jurek honed up his expertise in academia, designing DNA-based nanodevices and pioneering algorithms that pushed the boundaries of computation and nanoscale biology. His multidisciplinary approach has enabled him to translate breakthrough science into commercial biotech solutions, bridging the gap between research and real-world applications.</p>
<div class="lb-trans"><p>在创办 Nanovery 之前，Jurek 在学术界磨练了他的专业知识，设计基于 DNA 的纳米设备，并开创了推动计算和纳米生物学边界的算法。他的多学科方法使他能够将突破性的科学转化为商业生物技术解决方案，弥合研究与现实世界应用之间的差距。</p>
</div><p>At Nanovery, Jurek's mission is to drive innovation in the bioanalysis of RNA drugs, from high-throughput assay development to advanced data analytics, enabling safer and more effective treatments for complex diseases. His work has garnered attention from leading academics, industry partners, and cross-functional teams, solidifying his reputation as a visionary in the biotech space.</p>
<div class="lb-trans"><p>在 Nanovery，Jurek 的使命是推动 RNA 药物生物分析的创新，从高通量检测开发到先进的数据分析，使复杂疾病的治疗更加安全和有效。他的工作引起了领先学术界、行业合作伙伴和跨职能团队的关注，巩固了他在生物技术领域的远见卓识。</p>
</div><p><strong>About Karla Jo Helms</strong></p>
<div class="lb-trans"><p><strong>关于 Karla Jo Helms</strong></p>
</div><p>Karla Jo Helms is the Chief Evangelist and Anti-PR® Strategist for JOTO PR Disruptors™. Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line — and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumnus of crisis management, Karla Jo has worked with litigation attorneys, private investigators, and the media to help restore companies of goodwill into the good graces of public opinion — Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way, and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.</p>
<div class="lb-trans"><p>Karla Jo Helms 是 JOTO PR Disruptors™的首席传播官和反公关战略家。Karla Jo 亲身体验了当数百万美元处于风险之中时，商业是多么无情——以及公众舆论的控制往往决定了一家公司是被愉快选择，还是被残酷拒绝。作为危机管理的校友，Karla Jo 与诉讼律师、私人调查员和媒体合作，帮助恢复企业的良好声誉，使其重新赢得公众的信任——Karla Jo 秉持一次性做对的伦理，不依赖第二次机会，竭尽所能追求卓越。Helms 在全球范围内就公共关系发表演讲，探讨公关行业如何迷失方向，以及在正确的手中，企业如何利用反公关的力量来推动市场并影响市场认知。</p>
</div><p><strong>References</strong></p>
<div class="lb-trans"><p><strong>参考文献</strong></p>
</div><ol>
<li>Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., &amp; Southall, N. (2023). Clinical development times for innovative drugs. Nature Reviews Drug Discovery, 21(11). doi.org/10.1038/d41573-021-00190-9</li>
</ol>
<div class="lb-trans"><ol>
<li>Brown, D. G., Wobst, H. J., Kapoor, A., Kenna, L. A., &amp; Southall, N. (2023). 创新药物的临床开发时间。《自然评论：药物发现》，21(11)。doi.org/10.1038/d41573-021-00190-9</li>
</ol>
</div><p>Media Inquiries:</p>
<div class="lb-trans"><p>媒体咨询：</p>
</div><p>Karla Jo Helms</p>
<div class="lb-trans"><p>Karla Jo Helms</p>
</div><p>JOTO PR™</p>
<div class="lb-trans"><p>JOTO PR™</p>
</div><p>727-777-4629</p>
<div class="lb-trans"><p>727-777-4629</p>
</div><p>SOURCE Disruption Interruption</p>
<div class="lb-trans"><p>来源：Disruption Interruption</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTE1Jk5ld3NJdGVtSWQ9Rkw2NDY1OCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMTUxNjA2UFJfTkVXU19VU1BSX19fX19GTDY0NjU4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=FL64658&amp;Transmission_Id=202601151606PR_NEWS_USPR_____FL64658&amp;DateId=20260115"/></p>

颠覆生物技术：Jurek Kozyra 推出 DNA 纳米机器人，有望治愈那些被认为无法治愈的疾病